JCR Pharmaceuticals Co., Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2025. For the full year, the company expected net sales of JPY 41,300 million, operating profit of JPY 5,400 million, profit attributable to owners of parent of JPY 3,700 million and basic earnings per share of JPY 29.65.